Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6788)
All Articles published online
|
Publishing Process of This Article
|
Dec 26, 2021 (publication date) through Jul 2, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 [PMID: 35071559 DOI: 10.12998/wjcc.v9.i36.11285] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v9/i36/11285.htm |
| Number | Citing Articles |
| 1 |
Isabel Carbery, Gemma Burdge, Tanya Clark, Giacomo Broglio, Dan Greer, Alaa Alakkari, Christian Philipp Selinger. Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13). BMJ Open Gastroenterology 2023; 10(1): e001105 doi: 10.1136/bmjgast-2023-001105
|
| 2 |
Jose M. Huguet, Victor García-Lorenzo, Lidia Martí, Jose María Paredes, Jose Joaquin Ramírez, Miguel Pastor, Lucia Ruiz, Ana Sanahuja, Pilar Timoneda, Laura Sanchís, Gloria Alemany Pérez, Marta Maia Boscá-Watts. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. Biomedicines 2022; 10(9): 2130 doi: 10.3390/biomedicines10092130
|
| 3 |
Gary R. Lichtenstein, Arif Soonasra, Mark Latymer, Sheena Singh, Brian G. Feagan. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease. Expert Opinion on Biological Therapy 2024; 24(7): 691 doi: 10.1080/14712598.2024.2378090
|
| 4 |
Léa Sequier, Bénédicte Caron, Silvio Danese, Laurent Peyrin-Biroulet. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness. Expert Opinion on Biological Therapy 2024; 24(10): 1145 doi: 10.1080/14712598.2024.2401616
|